دورية أكاديمية
أعرض في EDS

Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC.

التفاصيل البيبلوغرافية
العنوان: Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC.
المؤلفون: Khan FB; Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont., Gibson PC; Department of Pathology & Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont., Anderson S; Department of Pathology & Laboratory Medicine, University of Vermont College of Medicine, Burlington, Vermont., Wagner S; Division of Pulmonary and Critical Care, Larner College of Medicine at the University of Vermont, Burlington, Vermont., Cole BF; Department of Mathematics and Statistics, University of Vermont, Burlington, Vermont., Kaufman P; Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont., Kinsey CM; Division of Pulmonary and Critical Care, Larner College of Medicine at the University of Vermont, Burlington, Vermont.
المصدر: JTO clinical and research reports [JTO Clin Res Rep] 2024 Jan 13; Vol. 5 (3), pp. 100634. Date of Electronic Publication: 2024 Jan 13 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: [New York] : Elsevier Inc., [2020]-
مستخلص: Neoadjuvant intratumoral cisplatin has the potential to generate substantial cytotoxicity and immune priming within the tumor environment, while minimizing systemic, off-target, adverse events. We initiated a phase 1A, 3+3 dose-ranging study of neoadjuvant, intratumoral cisplatin, delivered through endobronchial ultrasound bronchoscopy, in the same procedure as the initial diagnosis. There were no dose-limiting toxicity identified at the 20mg level.
Competing Interests: Dr. Kinsey has received support from Johnson and Johnson, Nanology, Galvanize Therapeutics and Olympus America and holds patents with Quantitative Imaging Solutions, the University of Vermont and Johnson and Johnson; he holds stock in Quantitative Imaging Solutions and is on the external advisory board on Interventional Oncology of Johnson and Johnson. Dr. Cole has received fees from the Frontier Science and Technology Research Foundation and Insmed and has received payments from the Ipsen EZH302 Study, the Aadi TSC-007n study, BrainStorm Cell Therapeutics, Acrotech Biopharma, CSL Behring, Genentech, GSK and Oncopeptides. The other authors have no funding or relationships to declare.
(© 2024 The Authors.)
References: Lung Cancer. 2015 Dec;90(3):542-7. (PMID: 26477968)
J Clin Diagn Res. 2016 Jul;10(7):XC01-XC04. (PMID: 27630935)
N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847)
Eur Respir Rev. 2020 Jun 16;29(156):. (PMID: 32554757)
Sci Rep. 2019 May 2;9(1):6819. (PMID: 31048709)
Ann Am Thorac Soc. 2015 Jan;12(1):101-4. (PMID: 25513850)
J Thorac Dis. 2020 Sep;12(9):4825-4832. (PMID: 33145055)
Respir Med Res. 2023 Nov;84:100994. (PMID: 37307616)
Sci Rep. 2022 Jan 7;12(1):44. (PMID: 34996946)
J Immunother Cancer. 2018 Dec 22;6(1):155. (PMID: 30577837)
Nat Rev Clin Oncol. 2021 Sep;18(9):558-576. (PMID: 34006998)
Clin Cancer Res. 2014 Nov 1;20(21):5384-91. (PMID: 25204552)
Am Soc Clin Oncol Educ Book. 2021 Jun;41:e133-e144. (PMID: 34061563)
فهرسة مساهمة: Keywords: Cisplatin; Endobronchial ultrasound-guided transbronchial needle injection; Intratumoral therapy; Lung cancer
تواريخ الأحداث: Date Created: 20240308 Latest Revision: 20240309
رمز التحديث: 20240309
مُعرف محوري في PubMed: PMC10918561
DOI: 10.1016/j.jtocrr.2024.100634
PMID: 38455594
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-3643
DOI:10.1016/j.jtocrr.2024.100634